Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-29141571

ABSTRACT

BACKGROUND AND OBJECTIVE: The cardioprotective properties of Mediterranean Diet were demonstrated for the first time from the Seven Country Study. In the last few decades, numerous epidemiological studies, as well as intervention trial, confirmed this observation, pointing out the close relationship between the Mediterranean diet and cardiovascular diseases. In this context, extra virgin olive oil (EVOO), the most representative component of this diet, seems to be relevant in lowering the incidence of cardiovascular events, including myocardial infarction and stroke. From a chemical point of view, 98-99% of the total weight of EVOO is represented by fatty acids, especially monounsaturated fatty acids such as oleic acid. Tocopherols, polyphenols and other minor constituents represent the remaining 1-2%. All these components may potentially contribute to "health maintenance" with their beneficial effects by EVOOO. METHODS: Studies that examined the effect of EVOO supplementation in healthy subjects and in individuals at cardiovascular risk were included. CONCLUSION: The studies analyzed demonstrated the role of EVOO as anti-inflammatory, antioxidant and vasodilatory nutrient that may contribute to lower the atherosclerotic burden.


Subject(s)
Cardiovascular Diseases/prevention & control , Diet, Mediterranean , Food Quality , Functional Food , Immunomodulation , Olive Oil/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/standards , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/standards , Antioxidants/therapeutic use , Cardiovascular Diseases/diet therapy , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/immunology , Dietary Supplements , Functional Food/standards , Humans , Olive Oil/standards , Risk , Vasodilator Agents/standards , Vasodilator Agents/therapeutic use
2.
Int J Cardiol ; 243: 421-423, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28610961

ABSTRACT

BACKGROUND: Although adipose stromal cells (ASCs) retain the ability to transdifferentiate at low rate towards the cardiac lineage, the potential mechanisms underlying such process have still to be elucidated. METHODS: Since chromatin state modifications are involved in several processes regulating the cellular cell fate commitment, we aimed at evaluating the role of histone protein acetylation in the cardiovascular-like transdifferentiation of ASCs. RESULTS: We found a clear increase of histone 3 acetylation status paralleled by a significant upregulation of cardiac TnI gene expression, in ASCs treated with the conditioned medium of primary cardiomyocyte cell cultures for 72h. This result suggests that histone acetylation contributes to the transdifferentiation of ASCs towards the cardiac lineage. In order to directly test this hypothesis, ASCs cultured with regular medium were treated with SAHA, a pan histone deacetylase inhibitor. We found that SAHA enhanced the cardiac permissive state of ASCs, increasing both mRNA and protein expression of cardiovascular genes, particularly cTnI. This suggests that histone acetylation induction is sufficient to promote cardiovascular transdifferentiation. CONCLUSIONS: The control of ASC fate by epigenetic regulators might be an interesting tool to boost both cardiac commitment and regenerative capacities of ASCs.


Subject(s)
Adipose Tissue/cytology , Adipose Tissue/metabolism , Histone Acetyltransferases/metabolism , Histone Deacetylase Inhibitors/pharmacology , Myocytes, Cardiac/metabolism , Acetylation/drug effects , Adipocytes/drug effects , Adipocytes/metabolism , Adipose Tissue/drug effects , Aged , Animals , Animals, Newborn , Female , Histone Acetyltransferases/antagonists & inhibitors , Humans , Middle Aged , Myocytes, Cardiac/drug effects , Rats , Stromal Cells/metabolism
3.
Mech Ageing Dev ; 159: 37-43, 2016 10.
Article in English | MEDLINE | ID: mdl-27181082

ABSTRACT

Senescence exerts a great impact on both biological and functional properties of circulating endothelial progenitor cells (EPCs), especially in cardiovascular diseases where the physiological process of aging is accelerated upon clinical administration of certain drugs such as doxorubicin. EPC impairment contributes to doxorubicin-induced cardiotoxicity. Doxorubicin accelerates EPC aging, although mechanisms underlying this phenomenon remain to be fully clarified. Here we investigated if Nox2 activity is able to modulate the premature senescence induced in vitro by doxorubicin in human EPCs. Results showed that in conditioned media obtained from late EPC cultures, the levels of interleukin-6, isoprostanes and nitric oxide bioavailability were increased and reduced respectively after 3h of doxorubicin treatment. These derangements returned to physiological levels when cells were co-treated with apocynin or gp91ds-tat (antioxidant and specific Nox2 inhibitors, respectively). Accordingly, Nox2 activity resulted to be activated by doxorubicin. Importantly, we found that Nox2 inhibition reduced doxorubicin-induced EPC senescence, as indicated by a lower percentage of ß-gal positive EPCs. In conclusion, Nox2 activity efficiently contributes to the mechanism of oxidative stress-induced increase in premature aging conferred by doxorubicin. The importance of modulation of Nox2 in human EPCs could reveal a useful tool to restore EPC physiological function and properties.


Subject(s)
Cellular Senescence/drug effects , Doxorubicin/adverse effects , Endothelial Progenitor Cells/metabolism , NADPH Oxidase 2/metabolism , Cells, Cultured , Doxorubicin/pharmacology , Endothelial Progenitor Cells/pathology , Humans , Interleukin-6/metabolism , Isoprostanes/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...